Holocene Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Holocene Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50,607	Closed	-$713K	–	787
2022 Q2	$713K	Buy	+50,607	New	+$944K	﹤0.01%	687
2018 Q2	–	Sell	-10,047	Closed	-$226K	–	562
2018 Q1	$226K	Sell	10,047 -1,021	-9%	-$28.3K	0.01%	494
2017 Q4	$333K	Buy	+11,068	New	+$354K	0.01%	517

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Holocene Advisors's ACAD Position: Q3 2022 in Review

Holocene Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 50,607 shares — an estimated $713K sold.

Holocene Advisors first reported a position in ACAD in Q4 2017 and held it in 3 quarters. The position peaked at $713K in Q2 2022. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

Holocene Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Holocene Advisors sold 50,607 Acadia Pharmaceuticals shares in Q3 2022, an estimated $713K.
Holocene Advisors first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 3 quarters.
Holocene Advisors's Acadia Pharmaceuticals position peaked at $713K in Q2 2022.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Holocene Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.